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Abstract
Objectives: The purpose of this study was to describe the use, as well as perceived effectiveness, of mainstream
and complementary and alternative medicine (CAM) therapies in the treatment of lymphedema following breast
or gynecological cancer. Further, the study assessed the relationship between the characteristics of lymphedema
(including type, severity, stability, and duration), and the use of CAM and/or mainstream treatment.
Methods: This was a cross-sectional study using a convenience sample of women with lymphedema following
breast and gynecological cancers. A self-administered questionnaire was sent to 247 potentially eligible women.
Of those returned (50%), 23 were ineligible and 6 were excluded due to level of missing data.
Results: In the previous 12 months, the majority of women (90%) had used mainstream treatments to treat their
lymphedema, with massage being the most commonly used (86%). One (1) in 2 women had used CAM to treat
their lymphedema, and 98% of those using CAM were also using mainstream treatments. Over 27 types of CAM
were reported, with use of a chi machine, vitamin E supplements, yoga, and meditation being the most com-
monly reported forms. The perceived effectiveness ratings (1–7 with 7 = completely effective) of mainstream
(mean – standard deviation (SD): 5.3 – 1.5) and CAM therapies (mean – SD: 5.2 + 1.6) were considered high.
Conclusions: These results demonstrate that mainstream and CAM treatment use is common, varied, and
considered to be effective among women with lymphedema following breast or gynecological cancer. Fur-
thermore, it highlights the immediate need for larger prospective studies assessing the inter-relationship be-
tween the use of mainstream and CAM therapies for treatment success.
Introduction
Lymphedema is a condition characterized by impaireddrainage of lymphatic fluid, commonly resulting in
swelling and skin changes.1 Mainstream or complementary
and alternative medicine (CAM) treatments for lymphedema
aim to reduce swelling, prevent progression, reduce risk of
infection, and alleviate associated symptoms.2 Early diag-
noses, rapid initiation of treatment, and high adherence to
treatment have been reported to optimize treatment success,3
and lack of treatment has been associated with lymphedema
progression.2 Unfortunately, access to treatment, associated
costs, and the time and/or discomfort associated with daily
treatment is considered unacceptable to some and may in-
fluence treatment effectiveness.4,5 The purpose of this study
was to describe the use and perceived effectiveness of main-
stream and CAM therapies in the treatment of lymphedema
following breast or gynecological cancer.
Methods
Self-administered questionnaires were sent to 247 mem-
bers of the Lymphedema Association of Queensland and
were returned by half of them (n = 124). A further 29 par-
ticipants were excluded due to ineligibility or missing data,
leaving data from 95 participants for analysis.
Information on demographic characteristics, lymphedema
characteristics, and lymphedema treatment types used were
collected via a self-administered questionnaire. Twenty-two
(22) treatment types were listed, and additional space was
provided to record unlisted treatments. Treatment types
were classified as CAM if they were considered an approach,
practice, or product that did not fit within conventional or
mainstream medicine.6 Perceived effectiveness of treatments
in improving symptoms of lymphedema was measured
using a 7-point Likert scale, whereby 0 denoted ‘‘not at all
effective’’ and 7 denoted ‘‘completely effective.’’
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Descriptive statistics were used to summarize personal
and lymphedema characteristics of the sample. Unadjusted
logistic regression was used to determine the relationship
between mainstream or CAM treatment use, and personal
and lymphedema characteristics. Statistical significance was
set at < 0.05 (two tailed) for all analysis. Data analyses were
performed using SPSS version 17.0.
Results
Characteristics of the sample are presented in Table 1. In
summary, all respondents were females and had undergone
surgical treatment for breast (84%) and/or gynecological cancer
(22%). Over two thirds (69%) reported household annual in-
comes of less than $50,000, and 63% were retired/on a pension.
Nearly 75% of the sample had upper-limb lymphedema,
18% had lower-limb lymphedema, and the remaining par-
ticipants (n = 7, 7%) had lymphedema in both upper and
lower limbs. A range of lymphedema severities were re-
ported, with 19%, 27%, and 13% of participants describing
their lymphedema as mild, moderate, and severe, respec-
tively. Those remaining (41%) reported experiencing a mix-
ture of symptom severities over the involved limb segments.
The majority (76%) described their lymphedema as fluctu-
ating in stability, and most of the respondents (70%) reported
having had lymphedema for longer than 5 years.
Table 2 provides the list of therapies used by participants
in the previous 12 months. Of those who reported using
CAM therapy in the previous 12 months (45% of sample),
more than half reported using two or more forms and 98%
also reported using some form of mainstream treatment. Use
of a chi machine, t’ai chi, vitamin E supplements, meditation,
and/or yoga were used by 21%–35% of those reporting CAM
therapies, while other forms of CAM including selenium
supplements, spiritual healing, reiki, naturopathy, acupunc-
ture, and homeopathy were reported by 5%–11%. The per-
ceived effectiveness of mainstream therapies (mean – SD:
5.3 – 1.5) and CAM therapies (mean– SD: 5.2 – 1.6) was sim-
ilar ( p= 0.53).
Compared with women 65 years or older, the odds of using
CAM were at least twofold higher for those aged 64 years or
less ( p= 0.05). Those with stable lymphedema also had higher
odds of using CAM (odds ratio [OR]= 4.95, 95% confidence
interval (CI)= 1.27–19.35, p< 0.05), compared with those who
described their lymphedema as fluctuating. Although not
statistically supported, employed women and women with
Table 1. Patient Characteristics
of the Sample (n = 95)
Patient characteristics n (%)
Age
18–54 years 10 (10.5)
55–64 years 37 (40.0)
65 years and older 48 (50.5)
Area
Major city 35 (38.4)
Regional area 42 (46.2)
Rural/remote area 14 (15.4)
Marital status
Living with partner 64 (67.4)
Living without partner 31 (32.6)
Employment status
Employed 20 (21.1)
Retired/disability pension 60 (63.1)
Home duties 15 (15.8)
Yearly household income
$0–$50 000 55 (68.8)
$50,000 and over 25 (31.2)
Private health insurance
Yes 75 (79.8)
No 19 (20.2)
Cancer typea
Breast 80 (84.2)
Gynecological 21 (22.1)
Skin 3 (3.2)
Melanoma 2 (2.1)
Bowel 3 (3.2)
Lymphoma 2 (2.1)
Bone 1 (1.1)
Lipsarcoma 1 (1.1)
Lung 1 (1.1)
Number of cancers
One cancers 76 (80.0)
Two cancers 18 (18.9)
Three cancers 1 (1.1)
Cancer treatmenta
Surgery 95 (100)
Radiation 69 (72.6)
Chemotherapy 37 (38.9)
Hormone 22 (23.2)
Other treatment 4 (4.2)
aMultiple responses possible.
Table 2. Treatment Types Used by People
with Lymphedema, Classified as Mainstream
or Complementary and Alternative Medicine
Mainstream treatment types
Compression garments/bandaging
Laser therapy
Limb exercises
Manual lymph drainage
Self-administered massage
Skin care
Ultrasound
Complementary and alternative medicine
Acupuncture
Aromatherapy
Bowen therapy
Chi machine
Chiropractic
Circulation booster
Detox water treatment
Homeopathy
Kinesiotape
Meditation
Naturopathy
Nurolink
Osteopathy
Reflexology
Reiki
Spiritual healing
T’ai chi
Pilates
Yoga
Vegetable bristle body brushing
Vitamin and mineral supplements
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yearly household incomes of $50,000 or more had higher odds
of using CAM therapy (OR= 2.41, 95% CI= 0.86–6.79 and
OR= 2.43, 95% CI= 0.92–6.39, respectively), compared with
those who were retired or did home duties and those with
incomes below $50,000 per year, respectively.
Discussion
Despite the high perceived effectiveness of mainstream
treatment, about 1 in 2 women reported multiple mainstream
treatments, and 1 in 2 also used at least one of the 22 CAM
therapies to treat their lymphedema during the same period.
CAM therapies may be used as an alternative treatment option
following poor response to mainstream lymphedema thera-
pies.7 However, since almost all women in our sample re-
porting the use of CAM also used mainstream therapies during
the same period, it seems more likely that CAM therapies were
considered complementary rather than alternative.
Previous work by others has described the financial, time,
and lifestyle burden of typical forms of mainstream treat-
ment options.8,9 Despite high perceived effectiveness ratings,
the burden may be sufficient to encourage those with lym-
phedema to source alternative treatment options. This may
be more likely for particular subgroups, such as younger
women and those who are employed, who were more likely
to use CAM treatments in this study. It could be assumed
that treatment options scoring similar or higher effectiveness
ratings that place lower burden on the women might become
the sole or alternative forms of treatment, replacing main-
stream options. Consequently, it seems plausible that while
the forms of CAM treatment reported were perceived to be
effective, multiple barriers prevented them from becoming
alternative forms of treatment.
Conclusions
The generalizability of the results presented is limited to
women who developed lymphedema following breast or
gynecological cancer, and the cross-sectional design pre-
cludes the identification of specific treatment effects on
lymphedema symptoms. All respondents were members of a
support organization and may not be representative of the
general secondary lymphedema population. In addition,
there were insufficient data to explore the use and effec-
tiveness of individual mainstream or CAM treatment mo-
dalities. Nonetheless, this work provides initial insight into
the extent of mainstream and CAM use in the treatment of
lymphedema following cancer, as well as the perceived ef-
fectiveness of such treatment from the perspective of the
patient. Given the extent and range of CAM therapies used
by women in this study, future research attention should be
given to the inter-relationship between mainstream and
CAM therapies for treatment success.
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